Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

TesamorelinIpamorelinCJC-1295 (with DAC)Sermorelin

Dimension	Tesamorelin Egrifta	Ipamorelin	CJC-1295 (with DAC) DAC:GRF	Sermorelin GRF 1-29
Evidence tier	AHuman RCT evidence	CPreclinical only	CPreclinical only	AHuman RCT evidence
Intelligence Score™	6.5/ 10 · Moderate	3.9/ 10 · Emerging	3.9/ 10 · Emerging	6.5/ 10 · Moderate
Family	GHRH analogue (stabilised)	Growth hormone secretagogue	GHRH analogue (long-acting)	GHRH analogue
Half-life	~26–38 min	~2 h	~6–8 days	~10–20 min
Typical dose	2 mg/day	200–300 mcg, 1–3× daily	1–2 mg/week	100–500 mcg/night
Routes	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous
Tier label	Human RCT	Preclinical only	Preclinical only	Human RCT
Mechanism	GHRH receptor agonist with N-terminal modification for stability.	Ghrelin (GHS-R1a) receptor agonist; pulses endogenous GH release.	GHRH receptor agonist; DAC binds albumin in vivo for extended exposure.	Endogenous GHRH receptor agonist; physiologic GH pulses.
Reported uses	weight-management	recovery-sleep	recovery-sleep	recovery-sleep
Contraindications	— Active malignancy — Pregnancy — Hypopituitarism	— Active malignancy — Pregnancy	— Active malignancy — Pregnancy	— Active malignancy — Hypothyroidism (uncontrolled)
Citations	1	1	1	1

AHuman RCT evidence

Intelligence Score™: 6.5/ 10 · Moderate
Family: GHRH analogue (stabilised)
Half-life: ~26–38 min
Typical dose: 2 mg/day
Routes: Subcutaneous
Tier label: Human RCT
Mechanism: GHRH receptor agonist with N-terminal modification for stability.
Reported uses: weight-management
Contraindications: — Active malignancy
— Pregnancy
— Hypopituitarism
Citations: 1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: Growth hormone secretagogue
Half-life: ~2 h
Typical dose: 200–300 mcg, 1–3× daily
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: Ghrelin (GHS-R1a) receptor agonist; pulses endogenous GH release.
Reported uses: recovery-sleep
Contraindications: — Active malignancy
— Pregnancy
Citations: 1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: GHRH analogue (long-acting)
Half-life: ~6–8 days
Typical dose: 1–2 mg/week
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: GHRH receptor agonist; DAC binds albumin in vivo for extended exposure.
Reported uses: recovery-sleep
Contraindications: — Active malignancy
— Pregnancy
Citations: 1

AHuman RCT evidence

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.